Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy
For prostate cancer patients who experience biochemical progression during androgen deprivation therapy (ADT), prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has not been prospectively compared to planar bone scan plus CT. This was a single-arm, hea...
Saved in:
Published in | Scientific reports Vol. 14; no. 1; pp. 24411 - 8 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
18.10.2024
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
ISSN | 2045-2322 2045-2322 |
DOI | 10.1038/s41598-024-75589-6 |
Cover
Abstract | For prostate cancer patients who experience biochemical progression during androgen deprivation therapy (ADT), prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has not been prospectively compared to planar bone scan plus CT. This was a single-arm, head-to-head, prospective phase II trial (NCT04928820) designed to enroll 102 men with prostate cancer who experienced biochemical progression (rising prostate-specific antigen [PSA] ≥ 1 ng/mL) during ADT. All patients received 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scans. Each scan was interpreted by three central independent readers. The primary endpoint was the per-patient bone metastasis detection rate of PSMA PET/CT versus planar bone scan and CT. Secondary endpoints compared the number of bone metastases detected per patient and the inter-reader agreement of each imaging modality. Twenty-two men were enrolled between July 2021 and June 2022. Due to slow accrual following approval of PSMA PET radiotracers in the U.S. and a lack of a statistical signal between the two imaging modalities on interim analysis, this trial was closed early on October 2022. Median PSA was 8.5 ng/mL (interquartile range: 1.6–77.6). There was 100% agreement between the two scans. Six patients (27%) had negative findings and 16 patients (73%) had positive findings on both scans. PSMA PET/CT and bone scan plus CT detected an equal number of bone lesions for 14 patients (64%), PSMA PET/CT detected more bone lesions for six patients (27%), and bone scan plus CT detected more bone lesions for two patients (9.1%) (p = 0.092). The inter-reader agreement rates of PSMA PET/CT and bone scan plus CT were 96% and 82%, respectively (
p
= 0.25). In men with biochemical progression during ADT, 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scan plus CT had identical bone metastasis detection rates. Bone scan plus CT can continue to serve as a cost-effective and readily accessible restaging modality in patients with biochemical progression. ClinicalTrials.gov NCT04928820. Registered 16/06/2021. |
---|---|
AbstractList | For prostate cancer patients who experience biochemical progression during androgen deprivation therapy (ADT), prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has not been prospectively compared to planar bone scan plus CT. This was a single-arm, head-to-head, prospective phase II trial (NCT04928820) designed to enroll 102 men with prostate cancer who experienced biochemical progression (rising prostate-specific antigen [PSA] ≥ 1 ng/mL) during ADT. All patients received 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scans. Each scan was interpreted by three central independent readers. The primary endpoint was the per-patient bone metastasis detection rate of PSMA PET/CT versus planar bone scan and CT. Secondary endpoints compared the number of bone metastases detected per patient and the inter-reader agreement of each imaging modality. Twenty-two men were enrolled between July 2021 and June 2022. Due to slow accrual following approval of PSMA PET radiotracers in the U.S. and a lack of a statistical signal between the two imaging modalities on interim analysis, this trial was closed early on October 2022. Median PSA was 8.5 ng/mL (interquartile range: 1.6-77.6). There was 100% agreement between the two scans. Six patients (27%) had negative findings and 16 patients (73%) had positive findings on both scans. PSMA PET/CT and bone scan plus CT detected an equal number of bone lesions for 14 patients (64%), PSMA PET/CT detected more bone lesions for six patients (27%), and bone scan plus CT detected more bone lesions for two patients (9.1%) (p = 0.092). The inter-reader agreement rates of PSMA PET/CT and bone scan plus CT were 96% and 82%, respectively (p = 0.25). In men with biochemical progression during ADT, 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scan plus CT had identical bone metastasis detection rates. Bone scan plus CT can continue to serve as a cost-effective and readily accessible restaging modality in patients with biochemical progression. ClinicalTrials.gov NCT04928820. Registered 16/06/2021.For prostate cancer patients who experience biochemical progression during androgen deprivation therapy (ADT), prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has not been prospectively compared to planar bone scan plus CT. This was a single-arm, head-to-head, prospective phase II trial (NCT04928820) designed to enroll 102 men with prostate cancer who experienced biochemical progression (rising prostate-specific antigen [PSA] ≥ 1 ng/mL) during ADT. All patients received 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scans. Each scan was interpreted by three central independent readers. The primary endpoint was the per-patient bone metastasis detection rate of PSMA PET/CT versus planar bone scan and CT. Secondary endpoints compared the number of bone metastases detected per patient and the inter-reader agreement of each imaging modality. Twenty-two men were enrolled between July 2021 and June 2022. Due to slow accrual following approval of PSMA PET radiotracers in the U.S. and a lack of a statistical signal between the two imaging modalities on interim analysis, this trial was closed early on October 2022. Median PSA was 8.5 ng/mL (interquartile range: 1.6-77.6). There was 100% agreement between the two scans. Six patients (27%) had negative findings and 16 patients (73%) had positive findings on both scans. PSMA PET/CT and bone scan plus CT detected an equal number of bone lesions for 14 patients (64%), PSMA PET/CT detected more bone lesions for six patients (27%), and bone scan plus CT detected more bone lesions for two patients (9.1%) (p = 0.092). The inter-reader agreement rates of PSMA PET/CT and bone scan plus CT were 96% and 82%, respectively (p = 0.25). In men with biochemical progression during ADT, 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scan plus CT had identical bone metastasis detection rates. Bone scan plus CT can continue to serve as a cost-effective and readily accessible restaging modality in patients with biochemical progression. ClinicalTrials.gov NCT04928820. Registered 16/06/2021. For prostate cancer patients who experience biochemical progression during androgen deprivation therapy (ADT), prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has not been prospectively compared to planar bone scan plus CT. This was a single-arm, head-to-head, prospective phase II trial (NCT04928820) designed to enroll 102 men with prostate cancer who experienced biochemical progression (rising prostate-specific antigen [PSA] ≥ 1 ng/mL) during ADT. All patients received 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scans. Each scan was interpreted by three central independent readers. The primary endpoint was the per-patient bone metastasis detection rate of PSMA PET/CT versus planar bone scan and CT. Secondary endpoints compared the number of bone metastases detected per patient and the inter-reader agreement of each imaging modality. Twenty-two men were enrolled between July 2021 and June 2022. Due to slow accrual following approval of PSMA PET radiotracers in the U.S. and a lack of a statistical signal between the two imaging modalities on interim analysis, this trial was closed early on October 2022. Median PSA was 8.5 ng/mL (interquartile range: 1.6-77.6). There was 100% agreement between the two scans. Six patients (27%) had negative findings and 16 patients (73%) had positive findings on both scans. PSMA PET/CT and bone scan plus CT detected an equal number of bone lesions for 14 patients (64%), PSMA PET/CT detected more bone lesions for six patients (27%), and bone scan plus CT detected more bone lesions for two patients (9.1%) (p = 0.092). The inter-reader agreement rates of PSMA PET/CT and bone scan plus CT were 96% and 82%, respectively (p = 0.25). In men with biochemical progression during ADT, 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scan plus CT had identical bone metastasis detection rates. Bone scan plus CT can continue to serve as a cost-effective and readily accessible restaging modality in patients with biochemical progression. ClinicalTrials.gov NCT04928820. Registered 16/06/2021. Abstract For prostate cancer patients who experience biochemical progression during androgen deprivation therapy (ADT), prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has not been prospectively compared to planar bone scan plus CT. This was a single-arm, head-to-head, prospective phase II trial (NCT04928820) designed to enroll 102 men with prostate cancer who experienced biochemical progression (rising prostate-specific antigen [PSA] ≥ 1 ng/mL) during ADT. All patients received 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scans. Each scan was interpreted by three central independent readers. The primary endpoint was the per-patient bone metastasis detection rate of PSMA PET/CT versus planar bone scan and CT. Secondary endpoints compared the number of bone metastases detected per patient and the inter-reader agreement of each imaging modality. Twenty-two men were enrolled between July 2021 and June 2022. Due to slow accrual following approval of PSMA PET radiotracers in the U.S. and a lack of a statistical signal between the two imaging modalities on interim analysis, this trial was closed early on October 2022. Median PSA was 8.5 ng/mL (interquartile range: 1.6–77.6). There was 100% agreement between the two scans. Six patients (27%) had negative findings and 16 patients (73%) had positive findings on both scans. PSMA PET/CT and bone scan plus CT detected an equal number of bone lesions for 14 patients (64%), PSMA PET/CT detected more bone lesions for six patients (27%), and bone scan plus CT detected more bone lesions for two patients (9.1%) (p = 0.092). The inter-reader agreement rates of PSMA PET/CT and bone scan plus CT were 96% and 82%, respectively (p = 0.25). In men with biochemical progression during ADT, 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scan plus CT had identical bone metastasis detection rates. Bone scan plus CT can continue to serve as a cost-effective and readily accessible restaging modality in patients with biochemical progression. ClinicalTrials.gov NCT04928820. Registered 16/06/2021. For prostate cancer patients who experience biochemical progression during androgen deprivation therapy (ADT), prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) has not been prospectively compared to planar bone scan plus CT. This was a single-arm, head-to-head, prospective phase II trial (NCT04928820) designed to enroll 102 men with prostate cancer who experienced biochemical progression (rising prostate-specific antigen [PSA] ≥ 1 ng/mL) during ADT. All patients received 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scans. Each scan was interpreted by three central independent readers. The primary endpoint was the per-patient bone metastasis detection rate of PSMA PET/CT versus planar bone scan and CT. Secondary endpoints compared the number of bone metastases detected per patient and the inter-reader agreement of each imaging modality. Twenty-two men were enrolled between July 2021 and June 2022. Due to slow accrual following approval of PSMA PET radiotracers in the U.S. and a lack of a statistical signal between the two imaging modalities on interim analysis, this trial was closed early on October 2022. Median PSA was 8.5 ng/mL (interquartile range: 1.6–77.6). There was 100% agreement between the two scans. Six patients (27%) had negative findings and 16 patients (73%) had positive findings on both scans. PSMA PET/CT and bone scan plus CT detected an equal number of bone lesions for 14 patients (64%), PSMA PET/CT detected more bone lesions for six patients (27%), and bone scan plus CT detected more bone lesions for two patients (9.1%) (p = 0.092). The inter-reader agreement rates of PSMA PET/CT and bone scan plus CT were 96% and 82%, respectively ( p = 0.25). In men with biochemical progression during ADT, 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scan plus CT had identical bone metastasis detection rates. Bone scan plus CT can continue to serve as a cost-effective and readily accessible restaging modality in patients with biochemical progression. ClinicalTrials.gov NCT04928820. Registered 16/06/2021. |
ArticleNumber | 24411 |
Author | Shen, John Benz, Matthias R. Rettig, Matthew Alano, Rejah Djaïleb, Loïc Gafita, Andrei Hotta, Masatoshi Grogan, Tristan Sonni, Ida Nikitas, John Armstrong, Wesley Calais, Jeremie Farolfi, Andrea Czernin, Johannes Liu, Sandy |
Author_xml | – sequence: 1 givenname: John surname: Nikitas fullname: Nikitas, John organization: Department of Radiation Oncology, University of California – sequence: 2 givenname: Andrei surname: Gafita fullname: Gafita, Andrei organization: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine – sequence: 3 givenname: Matthias R. surname: Benz fullname: Benz, Matthias R. organization: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California – sequence: 4 givenname: Loïc surname: Djaïleb fullname: Djaïleb, Loïc organization: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California – sequence: 5 givenname: Andrea surname: Farolfi fullname: Farolfi, Andrea organization: Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna – sequence: 6 givenname: Masatoshi surname: Hotta fullname: Hotta, Masatoshi organization: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California – sequence: 7 givenname: Ida surname: Sonni fullname: Sonni, Ida organization: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Department of Radiological Sciences, University of California, Department of Experimental and Clinical Medicine, University Magna Graecia – sequence: 8 givenname: Rejah surname: Alano fullname: Alano, Rejah organization: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California – sequence: 9 givenname: Matthew surname: Rettig fullname: Rettig, Matthew organization: Departments of Medicine and Urology, University of California, Hematology-Oncology Section, Medicine Service, Greater Los Angeles Veterans Affairs Healthcare System – sequence: 10 givenname: John surname: Shen fullname: Shen, John organization: Departments of Medicine and Urology, University of California – sequence: 11 givenname: Wesley surname: Armstrong fullname: Armstrong, Wesley organization: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California – sequence: 12 givenname: Tristan surname: Grogan fullname: Grogan, Tristan organization: Department of Medicine Statistics Core, University of California – sequence: 13 givenname: Sandy surname: Liu fullname: Liu, Sandy organization: Department of Medical Oncology & Therapeutics Research, City of Hope – sequence: 14 givenname: Johannes surname: Czernin fullname: Czernin, Johannes organization: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California – sequence: 15 givenname: Jeremie surname: Calais fullname: Calais, Jeremie email: JCalais@mednet.ucla.edu organization: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39420060$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1u1DAQxyNUREvpC3BAlrhwCdhOHDvHalXaSkWsxHK2JvZkN6usE-ykVR-Bt2Z2txTEAcuSrb9_8-l5nZ2EIWCWvRX8o-CF-ZRKoWqTc1nmWilT59WL7EzyUuWykPLkr_tpdpHSltNSsi5F_So7LepScl7xs-zncgMJmWRT7KBnQ8uW375csuXVii1W7B5jmhMbewgQWUMZsOQgMAh-_9wFNsYhTTAhI9lhZCNMHYYp7R_WEVPqwpo9bLoe2XCwIxkD8zjG7p5YEqcNRhgf32QvW-gTXjyd59n3z1erxU1-9_X6dnF5l7uyqKZcaOUr531lXGu0rhRKgBJ9LRukrXTNNTgnjADTtq4S2JTGFVppwxvtsTjPbo9-_QBbS2nsID7aATp7EIa4thCnzvVopZcKKl9oUHXpdWP2AdqqUdDUJCjy9eHoi6r9MWOa7K5LDnvqFw5zsoUQmkguSkLf_4NuhzkGqvRAaaOE4US9e6LmZof-Ob3fH0aAPAKOGp8its-I4HY_GPY4GJYGwx4Gw1ZkVByNEsFhjfFP7P9Y_QKrWbo8 |
Cites_doi | 10.1056/NEJMoa1911206 10.2967/jnumed.120.245456 10.2967/jnumed.123.265916 10.1155/2017/7039406 10.1016/S0140-6736(20)30314-7 10.1056/NEJMoa1213755 10.1158/1078-0432.CCR-19-1050 10.1056/NEJMoa1209096 10.1056/NEJMoa040720 10.1056/NEJMoa1405095 10.1007/s11307-018-1278-8 10.1007/s00259-023-06332-y |
ContentType | Journal Article |
Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 DOA |
DOI | 10.1038/s41598-024-75589-6 |
DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2045-2322 |
EndPage | 8 |
ExternalDocumentID | oai_doaj_org_article_2d25a6d37a594d7b82be5f6b5ab994d5 39420060 10_1038_s41598_024_75589_6 |
Genre | Clinical Trial, Phase II Journal Article Comparative Study |
GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: T32 GM008042 |
GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB PUEGO 7XB 8FK AARCD K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 |
ID | FETCH-LOGICAL-c436t-175d6cdd68cf87765e2aa4ed92be2be57907acc181a8ffc61eb48c375780b7de3 |
IEDL.DBID | M48 |
ISSN | 2045-2322 |
IngestDate | Wed Aug 27 01:21:36 EDT 2025 Fri Sep 05 04:06:24 EDT 2025 Wed Aug 13 09:16:37 EDT 2025 Fri Sep 26 01:52:57 EDT 2025 Tue Jul 01 03:23:14 EDT 2025 Fri Feb 21 02:36:54 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Prostate-specific membrane antigen PET/CT Androgen deprivation therapy Biochemical recurrence Bone metastases Bone scan |
Language | English |
License | 2024. The Author(s). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c436t-175d6cdd68cf87765e2aa4ed92be2be57907acc181a8ffc61eb48c375780b7de3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/3117785180?pq-origsite=%requestingapplication%&accountid=15518 |
PMID | 39420060 |
PQID | 3117785180 |
PQPubID | 2041939 |
PageCount | 8 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_2d25a6d37a594d7b82be5f6b5ab994d5 proquest_miscellaneous_3117994014 proquest_journals_3117785180 pubmed_primary_39420060 crossref_primary_10_1038_s41598_024_75589_6 springer_journals_10_1038_s41598_024_75589_6 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-10-18 |
PublicationDateYYYYMMDD | 2024-10-18 |
PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-18 day: 18 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Scientific reports |
PublicationTitleAbbrev | Sci Rep |
PublicationTitleAlternate | Sci Rep |
PublicationYear | 2024 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | Hirmas (CR2) 2019; 21 Parker (CR10) 2013; 369 Tannock (CR8) 2004; 351 Holzgreve (CR11) 2023; 50 CR5 Rager (CR12) 2017; 2017 Hope (CR13) 2023; 64 Weber (CR4) 2021; 62 Hofman (CR1) 2020; 395 de Wit (CR9) 2019; 381 Fendler (CR3) 2019; 25 Beer (CR7) 2014; 371 Ryan (CR6) 2013; 368 N Hirmas (75589_CR2) 2019; 21 WP Fendler (75589_CR3) 2019; 25 75589_CR5 R de Wit (75589_CR9) 2019; 381 CJ Ryan (75589_CR6) 2013; 368 M Weber (75589_CR4) 2021; 62 O Rager (75589_CR12) 2017; 2017 TM Beer (75589_CR7) 2014; 371 IF Tannock (75589_CR8) 2004; 351 A Holzgreve (75589_CR11) 2023; 50 C Parker (75589_CR10) 2013; 369 TA Hope (75589_CR13) 2023; 64 MS Hofman (75589_CR1) 2020; 395 |
References_xml | – volume: 381 start-page: 2506 year: 2019 end-page: 2518 ident: CR9 article-title: Cabazitaxel versus Abiraterone or Enzalutamide in metastatic prostate Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1911206 – volume: 62 start-page: 88 year: 2021 end-page: 91 ident: CR4 article-title: PSMA-Ligand PET for early castration-resistant prostate Cancer: a retrospective single-center study publication-title: J. Nucl. Med. doi: 10.2967/jnumed.120.245456 – volume: 64 start-page: 1744 year: 2023 end-page: 1747 ident: CR13 article-title: Do bone scans overstage Disease compared with PSMA PET at initial staging? An International Multicenter Retrospective study with masked independent readers publication-title: J. Nucl. Med. doi: 10.2967/jnumed.123.265916 – volume: 2017 start-page: 7039406 year: 2017 ident: CR12 article-title: Whole-body SPECT/CT versus Planar Bone scan with targeted SPECT/CT for metastatic workup publication-title: Biomed. Res. Int. doi: 10.1155/2017/7039406 – volume: 395 start-page: 1208 year: 2020 end-page: 1216 ident: CR1 article-title: Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study publication-title: Lancet doi: 10.1016/S0140-6736(20)30314-7 – volume: 369 start-page: 213 year: 2013 end-page: 223 ident: CR10 article-title: Alpha Emitter Radium-223 and survival in metastatic prostate Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1213755 – volume: 25 start-page: 7448 year: 2019 end-page: 7454 ident: CR3 article-title: Prostate-specific membrane Antigen Ligand Positron Emission Tomography in men with Nonmetastatic Castration-resistant prostate Cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-1050 – volume: 368 start-page: 138 year: 2013 ident: CR6 article-title: Randomized phase 3 trial of Abiraterone acetate in men with metastatic castration-resistant prostate Cancer and no prior chemotherapy publication-title: N Engl. J. Med. doi: 10.1056/NEJMoa1209096 – volume: 351 start-page: 1502 year: 2004 end-page: 1512 ident: CR8 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer publication-title: N Engl. J. Med. doi: 10.1056/NEJMoa040720 – ident: CR5 – volume: 371 start-page: 424 year: 2014 end-page: 433 ident: CR7 article-title: Enzalutamide in metastatic prostate Cancer before Chemotherapy publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1405095 – volume: 21 start-page: 574 year: 2019 end-page: 581 ident: CR2 article-title: [ Ga]PSMA PET/CT improves initial staging and management plan of patients with high-risk prostate Cancer publication-title: Mol. Imaging Biol. doi: 10.1007/s11307-018-1278-8 – volume: 50 start-page: 3750 issue: 12 year: 2023 end-page: 3754 ident: CR11 article-title: Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-023-06332-y – volume: 25 start-page: 7448 year: 2019 ident: 75589_CR3 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-1050 – volume: 368 start-page: 138 year: 2013 ident: 75589_CR6 publication-title: N Engl. J. Med. doi: 10.1056/NEJMoa1209096 – volume: 395 start-page: 1208 year: 2020 ident: 75589_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(20)30314-7 – ident: 75589_CR5 – volume: 64 start-page: 1744 year: 2023 ident: 75589_CR13 publication-title: J. Nucl. Med. doi: 10.2967/jnumed.123.265916 – volume: 381 start-page: 2506 year: 2019 ident: 75589_CR9 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1911206 – volume: 62 start-page: 88 year: 2021 ident: 75589_CR4 publication-title: J. Nucl. Med. doi: 10.2967/jnumed.120.245456 – volume: 2017 start-page: 7039406 year: 2017 ident: 75589_CR12 publication-title: Biomed. Res. Int. doi: 10.1155/2017/7039406 – volume: 371 start-page: 424 year: 2014 ident: 75589_CR7 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1405095 – volume: 369 start-page: 213 year: 2013 ident: 75589_CR10 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1213755 – volume: 50 start-page: 3750 issue: 12 year: 2023 ident: 75589_CR11 publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-023-06332-y – volume: 351 start-page: 1502 year: 2004 ident: 75589_CR8 publication-title: N Engl. J. Med. doi: 10.1056/NEJMoa040720 – volume: 21 start-page: 574 year: 2019 ident: 75589_CR2 publication-title: Mol. Imaging Biol. doi: 10.1007/s11307-018-1278-8 |
SSID | ssj0000529419 |
Score | 2.4466326 |
Snippet | For prostate cancer patients who experience biochemical progression during androgen deprivation therapy (ADT), prostate-specific membrane antigen positron... Abstract For prostate cancer patients who experience biochemical progression during androgen deprivation therapy (ADT), prostate-specific membrane antigen... |
SourceID | doaj proquest pubmed crossref springer |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | 24411 |
SubjectTerms | 631/67/1344 631/67/589/466 692/308/2779/109 692/4028/67/2321 692/700/1421/1771 692/700/1421/2109 692/700/1421/2770 Aged Aged, 80 and over Androgen Antagonists - therapeutic use Androgen deprivation therapy Androgens Antigens Antigens, Surface - metabolism Biochemical recurrence Bone and Bones - diagnostic imaging Bone and Bones - drug effects Bone and Bones - metabolism Bone and Bones - pathology Bone cancer Bone imaging Bone lesions Bone metastases Bone Neoplasms - diagnostic imaging Bone Neoplasms - drug therapy Bone Neoplasms - secondary Bone scan Computed tomography Disease Progression Gallium Isotopes Gallium Radioisotopes Glutamate Carboxypeptidase II - metabolism Humanities and Social Sciences Humans Lesions Male Metastases Metastasis Middle Aged multidisciplinary Patients Positron emission tomography Positron Emission Tomography Computed Tomography - methods Prospective Studies Prostate cancer Prostate-specific antigen Prostate-Specific Antigen - blood Prostate-specific membrane antigen PET/CT Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Radioactive tracers Radiopharmaceuticals Science Science (multidisciplinary) Scintigraphy Tomography Tomography, X-Ray Computed - methods |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6yIHgR37auUoI3bbYnSedxXJddFkEZcBb2FvJ0BekZpmeQ_Qn-aytJz7ii4sVr0kkn9VU6VV0vQl5zhsr_THRt52VqeeS0tSrM2hRdcpLR4H3xtvgozi_4-8v-8kapr-wTVtMDV8Id0UB7KwKTttc8SKeoi30SrrdOY0PJXoqvu6FM1azeVPOZnqJkOqaORrypcjQZ5a3se6Vb8ctNVBL2_0nK_M1CWi6es3vk7iQxwnFd6X1yKw4PyO1aQ_L6Ifk-v8KLCCiU-huwTDD_9OEY5qcLOFlAdrrYjrD6age7BrccIoxITLBDyN1fBljlsA8UOMFn_NcwJVodoXhuZSfZ4TN8u8KPByzLOGyOA2QP2qkwGtQYrutH5OLsdHFy3k71FVrPmdi0KDkE4UMQyiclpegjtZbHoJHEmcoSFWfrPcoAVqXkxSw6rjzLGfA7J0Nkj8nBgAt_SkBLlkTkCA-ixDUCHa3zXRA0dTop15A3O1qbVU2jYYr5mylTkTGIjCnIGNGQdxmO_ZM5BXZpQMYwE2OYfzFGQw53YJrpXI6GZRs1Cpmqa8irfTeeqGwmsUNcbuszOAPqjg15UplgvxKmef4Hg6Pf7rji5-R_39Cz_7Gh5-QOzeyb3WnUITnYrLfxBUpEG_eyMP8PiI8HSg priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1raxQxMNQrgl_Et6dVRvCbLt1LstnsB5G2XCmCx6FX6Lclz7Ygu-c9kP4E_7Uz2d0r4gP2U56zmUlmknkx9lYKvPxPVJ7lroyZDJJnRvtJFoONthTcO5esLWbq7Fx-uigu9ths8IUhs8rhTEwHtW8dvZEfCtIuonig84_L7xlljSLt6pBCw_SpFfyHFGLsDtvnlFV5xPaPp7P5l92rC-m15KTqvWdyoQ_XyMHIy4zLrCwKXWXqNw6VAvn_Tfr8Q3OaGNLpA3a_lyThqEP9Q7YXmkfsbpdb8uYx-zm_QgYFHFJeDmgjzL9-PoL5dAEnCyBjjO0alt9MY1Zg2ybAGhcZTOOp-rqBJbmDoCAKjuhiBX0A1jUkiy4ynm0u4ccVHirQpn5YHBogy9o-YRp0vl03T9j56XRxcpb1eRcyJ4XaZChReOW8V9pFXZaqCNwYGXzFbcCvKPFCjQuOsoHRMTo1CVZqJygyfm5LH8RTNmoQ8OcMqlJEFWRpdVFJWSEBBGNd7hWPeRW1HbN3w1rXyy68Rp3U4kLXHWZqxEydMFOrMTsmdOxaUmjsVNCuLut-p9Xc88IoL0qDU3qcmUCOyhbGVlhQjNnBgMy636_r-pa6xuzNrhp3GqlPTBPabdcGR8A75Zg964hgB4moJL3NYO_3A1XcDv7vH3rxf1hesnucCJMMaPQBG21W2_AKZaCNfd0T9i-UYgTP priority: 102 providerName: ProQuest – databaseName: SpringerOpen Free (Free internet resource, activated by CARLI) dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1daxQxMNSK4ItYP1dbGcE3XdxLskn2sR4tpVA58Ap9C_lshbJ73N4h_Qn-ayfZ3ROxPgj7lM_ZzCQzyXwR8oEzvPzPRFVWTsaSB05Lo_ysjMFGKxn1zmVri6_i7JKfX9VXe4ROvjDZaD-HtMzH9GQd9rlHRpOcwSgvZV2rphQPyEMlkVsmBa2Y795VkuaKz5rRP6Zi6p6uf_CgHKr_PvnyL91oZjmnT8mTUVaE4wG6A7IX2mfk0ZA98u45-bm4QRYEFHLmDegiLL5dHMPiZAnzJSRzi20Pq1vTmjXYrg3Q4zKCaX2q_t7CKjl8oKgJLmF-DWOI1R6yzVYyj22v4ccNHhvQ5X5YHFpItrNjSjQYvLfuXpDL05Pl_KwcMyuUjjOxKVFm8MJ5L5SLSkpRB2oMD76hNuBXS7wyG-eQ-xsVoxOzYLlyLMW-r6z0gb0k-y0C_ppAI1kUgUur6obzBlEcjHWVFzRWTVS2IB-ntdarIYCGzopvpvSAGY2Y0RkzWhTkS0LHrmUKfp0LuvW1HolBU09rIzyTBqf0OHMCOQpbG9tgQV2QwwmZetyRvWZJO43ipaoK8n5XjXspKUhMG7rt0AZHwFtjQV4NRLCDhDU8vb5g708TVfwe_N8_9Ob_mr8lj2ki1GQyow7J_ma9DUco9Wzsu0zmvwDB_fwi priority: 102 providerName: Springer Nature |
Title | Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy |
URI | https://link.springer.com/article/10.1038/s41598-024-75589-6 https://www.ncbi.nlm.nih.gov/pubmed/39420060 https://www.proquest.com/docview/3117785180 https://www.proquest.com/docview/3117994014 https://doaj.org/article/2d25a6d37a594d7b82be5f6b5ab994d5 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba9swFBa9MNjL2H3uunAGe9u8ObIsyQ9jpCGlBFrCmkDejK7toDhZLnT5CfvXO5KdjLHsYWAwSLJu58jnk3QuhLxjOW7-uzxLMyN8yhyjqZK2m3qnvRY5tcZEbYsrfjFhw2kxPSDbcEftBC73bu1CPKnJ4u7jj--bL7jgPzcm4_LTEoVQMBSjLBVFIcuUH5JjlEw0cPllC_cbX9-0ZDHWR3DCniKYoK0dzf5q_pBV0aX_Phz61x1qFE3nj8mjFlNCr2GCJ-TA1U_JgybK5OYZ-Tm6RVEFFGKEDph5GF1f9mA0GEN_DEEtY72E-Z2q1QL0rHawxOkGVduQ_a2GeTAMQUgKJnDIAlpXrEuIul1Bjba-gftb_L3ALH6Hya6GoGPbhk6Dxspr85xMzgfj_kXaRmBIDcv5KkVsYbmxlkvjpRC8cFQp5mxJtcOnELi1VsYgSlDSe8O7TjNp8uAjP9PCuvwFOaqx468IlCL33DGhZVEyViIrOKVNZjn1WemlTsj77VxX88bRRhUvyHNZNZSpkDJVpEzFE3IWyLErGZxkx4TZ4qZq11xFLS0Ut7lQ2KTFlkOXPdeF0iUmFAk53RKz2jJelYdbbIShMkvI2102rrlwkaJqN1s3ZbAG3F0m5GXDBLue5CULpzT49YctV_yu_N8DOvmv4b8mD2ng06BZI0_J0Wqxdm8QHK10hxyKqeiQ415veD3E99ngavQVU_u834kHDp24Jn4B3e4NFA |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0CqtEFwQbxYKGAlOEDVrO45zqFBbttrSdrWCrdSb8bOtVCXLZlfVfgI_xbcxdpKtEI9bpZwcPyaZsWfG80LoLaOg_Pd5mqQm9wlzjCRK2H7infY6p8QaE70tRnx4wj6fZqdr6GcXCxPcKrszMR7UtjLhjnyLBusiiAci_Tj9noSqUcG62pXQUG1pBbsdU4y1gR2HbnkFKly9ffAJ8P2OkP3BZG-YtFUGEsMonyfAPy031nJhvMhznjmiFHO2INrBk-WgPsL0wAmV8N7wvtNMGBrywKc6t47CvLfQBogdFHbVxu5gNP6yuuUJdjTWL9ponZSKrRo4ZohqIyzJs0wUCf-NI8bCAX-Tdv-w1EYGuH8f3WslV7zTkNoDtObKh-h2U8ty-Qj9GJ8DQ8QExzoguPJ4_PV4B48HE7w3wcH5Y1Hj6aUq1QzrqnS4BqRiVdrw-qLE0xB-AoIvNoEOZ7hN-Frj6EEWnHXLM3x1DocYruI4aHYlDp68bYE23MSSLR-jkxvBwBO0XgLgzxAucuq5Y7kWWcFYAQTnlDap5cSnhRe6h953_1pOm3QeMprhqZANZiRgRkbMSN5DuwEdq54hFXdsqGZnst3ZkliSKW5prmBJCysHkD3XmdIFNGQ9tNkhU7bnQy2vqbmH3qxew84O5hpVumrR9IEZQIftoacNEawgoQULd0Ew-kNHFdeT__uDnv8fltfoznByfCSPDkaHL9BdEog0OO-ITbQ-ny3cS5C_5vpVS-QYfbvpffULETVDMA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYgL4s1CASPBCaLN2o7tHBAqbVcthWoltlJvrp8tEkqWza6q_Qn8JX4dYyfZCvG4VcrJsR3H841n7JnxIPSKUdj8j3ie5VaEjHlGMi3dKAveBCMocdYmb4sjvn_MPp4UJxvoZx8LE90q-zUxLdSutvGMfEijdRHUA5kPQ-cWMdkdv599z2IGqWhp7dNptBA59KsL2L417w52gdavCRnvTXf2sy7DQGYZ5YsMZKfj1jkubZBC8MITrZl3JTEenkLA1lFbC1JQyxAsH3nDpKXxDvjcCOcp9HsNXRcUxDrwkjgR6_OdaEFjo7KL08mpHDYgK2M8G2GZKApZZvw3WZhSBvxNz_3DRptE3_gOut3prHi7BdldtOGre-hGm8VydR_9mJyDKMQEpwwguA548uXzNp7sTfHOFEe3j2WDZ990pefY1JXHDZAT68rF118rPIuBJ6DyYhsROMfdVa8NTr5j0U23OsMX57B84Tq1g2Jf4ejD26Vmw20U2eoBOr6S-X-INisY-GOES0ED90wYWZSMlQA1r43NHSchL4M0A_Smn2s1ay_yUMkAT6VqKaOAMipRRvEB-hDJsa4ZL-FOBfX8THU8rYgjheaOCg2fdPDlOOTATaFNCQXFAG31xFTdytCoSxwP0Mv1a-DpaKjRla-XbR3oAXavA_SoBcF6JLRk8RQIWr_tUXHZ-b9_6Mn_x_IC3QRuUp8Ojg6folskYjR67cgttLmYL_0zULwW5nlCOEanV81SvwBBEEDM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+2+trial+of+PSMA+PET+CT+versus+planar+bone+scan+and+CT+in+prostate+cancer+patients+progressing+while+on+androgen+deprivation+therapy&rft.jtitle=Scientific+reports&rft.au=Nikitas%2C+John&rft.au=Gafita%2C+Andrei&rft.au=Benz%2C+Matthias+R.&rft.au=Dja%C3%AFleb%2C+Lo%C3%AFc&rft.date=2024-10-18&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-024-75589-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_024_75589_6 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |